Arterial infusion chemotherapy from superficial temporal artery in combination with radiotherapy for early stage nasal NK/T-cell lymphoma

DOI
  • TAKAHARA Miki
    Department of Otolaryngology-Head and Neck Surgery,Asahikawa Medical College
  • OGINO Takeshi
    Department of Otolaryngology-Head and Neck Surgery,Asahikawa Medical College
  • HARABUCHI Yasuaki
    Department of Otolaryngology-Head and Neck Surgery,Asahikawa Medical College

Bibliographic Information

Other Title
  • 鼻性NK/T細胞リンパ腫に対する浅側頭動脈動注化学放射線同時併用療法

Search this article

Abstract

Nasal NK/T-cell lymphoma is an Epstein-Barr virus (EBV)-related aggressive neoplasm with poor prognosis. To improve the treatment outcome, we are trying arterial infusion chemotherapy from superficial temporal artery in combination with radiotherapy for early stage nasal NK/T-cell lymphoma. New regimen for the arterial infusion consist of fosfamide, carboplatin, methotrexate, peplomycin and etoposide (MPVIC-P). Fosfamide, carboplatin, methotrexate, and peplomycin are independent of multidrug resistance genes common- ly expressed in the lymphoma cells, and etoposide is known to be effective against lymphoma-associated hemophagocytic syndrome (LAHS), which frequently develops in the patients. From 2003, 5 patients with stage I nasal NK/T-cell lymphoma were treated by the arterial infusion of MPVIC-P regimen for 3 cycles and concomitant radiotherapy. Effect of the treatment was evaluated by local findings, CT and MRI findings, and EBV-DNA copy number in serum. All patients achieved complete remission (CR) and the 3-year disease free survival (DFS) rates were 100%. According to these results, arterial infusion chemotherapy from superficial temporal artery in combination with radiotherapy is effective treatment for early stage nasal NK/ T-cell lymphoma.

Journal

  • OTOLOGIA FUKUOKA

    OTOLOGIA FUKUOKA 53 (5Supplement1), S57-S63, 2007

    JIBI TO RINSHO KAI

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top